There are few reports of infection due to Mycobacterium simiae, particularly in non-Human Immudeficiency virus (HIV) patients. Mycobacterium simiae, an atypical mycobacterium, is recognised as an infection-causing agent in immunocompromised patients. We report a case of pulmonary infection due to M.simiae, associated with human T lymphothropic virus Type I (HTLV1) seropositivity, which to our knowledge, is the first case of Mycobacterium simiae and HTLV1 co-infection.
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Case presentation
A 51 year old married woman was referred to our hospital as a multi drug resistant case from Tabriz TB centre in the north western province of Iran (Eastern Azerbaijan). The disease had presented with cough and productive sputum since one year before admission. After 3 months, the patient, being diagnosed as a case of smear positive pulmonary tuberculosis, had received a 6 month anti tuberculosis regimen including first line drugs (Isoniazid, Rifampin, Ethambutol, and Pyrazinamid) according to standard World Health Organization (WHO) recommendations.
The sputum culture was positive in the end of 5th month of treatment, and antibiogram showed resistance to all first line anti tuberculosis drugs.
The patient was referred to our hospital for further investigation and subsequent treatment.
At the time of admission, she presented with mild cough and dispnea, chest pain, fever, night sweat and mild anorexia. She was a passive smoker without any history of TB or any other lung diseases. No tuberculosis history was found in patient's family.
Upon physical examination, she was neither ill nor cachectic.Vital signs were within normal range. In lung, fine disseminated, early inspiratory crackles were present in both fields. No organomegaly or lymphadenopathy was present.
The chest radiography and spiral thorax Computed Tomography scan are shown in figures 1 and 2.
Sputum culture in Lowenstein-Johnson medium revealed slowly growing photochromotogen, colonies. The organism was niacin positive, whereas it failed to reduce nitrate, and was also negative in Tween hydrolysis. Polymerase chain reaction and restriction fragment length polymorphism using primers (439-bp segment of gene encoding the 65-kDa heat shock protein) was performed in two separately cultured colonies mediums [1] . The mycobacterium was identified as Mycobacterium simiae by RFLP ( figure 3) .
We found more than 6 berculosis. In this case, for confirmation of absence M.tuberculosis, we also used molecular study.
The patient was referred to bronchoscopy, bronchoalveolar lavage and transbronchial lung biopsy when she was hospitalised. The pathology results revealed granulomoatous reaction that was compatible with mycobacterial infections.
The immunological variables were detected by the means of serology tests, flow cytometry and detecting antibodies of HIV and HTLV1.
The results of the laboratory tests of patient, including hematological, biochemical, immunological and Mycobacteriological tests are shown in table 1.
The patient went under multidrug-resistant regimen therapy with daily Ofloxacin (600 mg), Amikacin (500 mg), Cycloserine (500 mg), and Pyrazinamid (1500 mg).
With regard to the American Thoracic Society (ATS) criteria [2] , the diagnosis of non-tuberculous mycobacteria had been fulfilled and the therapeutic regimen was changed to Clarithomycin 500 mg BID, Ciprofloxacin 500 mg BID and Amikacin 500 mg daily.
The patient had negative smears and her clinical symptoms and signs were alleviated after three months.
Check-ups after six months of the treatment initiation, the patient's smears and cultures were repeatedly without any clinical complaint.
Discussion
There are reports of Mycobacterium simiae isolation from clinical specimens and different body sites, including the lungs as the most frequent site blood and bone marrow, skin, urine,lymphnode,brain, umbilical cord [3] [4] [5] [6] [7] [8] [9] . Yet, clinical disease reports are rare.
Mycobacterium simiae, originally isolated from monkeys in 1965, has been recovered from environmental origins such as soil samples, tap water, water supply and dental unit waterlines in different parts of world such as Israel, Gaza, central Africa, Europe, USA, Cuba and Australia as well [7, [9] [10] [11] . Although in some cases it may be attributed to the contamination or colonisation of Mycobacterium simiae, there is evidence, albeit rare, of active disease due to Mycobacterium simiae [3-6, 8, 12] .
The infection reported in both immunocompetent [5, 6, 8] and immunocompromised patients [2, 3, 8, 11 ] is thought to occur in immunocompromised patients including patients suffering from AIDS [3, 9] or other causes of immunocompromised states including corticosteroid therapy and solid organ tumour [4] .
To our knowledge, this is the first case of infection with Mycobacterium simiae together with HTLV1 seropositivity. Furthermore; this is the first case of Mycobacterium simiae pulmonary infection, reported from Iran.
However, there has been a recent report of pulmonary mycobacterium avium complex (M.A.C) [14] . Considering afore mentioned reports, Immunologic status seems to be a main determinant of disease development. With regard to the recent findings about altered immunologic status in HTLV1 carries [15] [16] [17] , HTLV1 carrier state might be considered to be a predisposing factor for the infection with Mycobacterium simiae in this case.
North eastern parts of Iran have been recognised as endemic regions of HTLV1 carrier state [18] , but there has been no report of any seropositivity or infection due to HTLV1 in other parts of Iran, such as the eastern Azerbaijan province, located in the north west of Iran, where the patient is from. It seems that in world regions such as Iran, where an endemicity of HTLV1 is documented, there must be a high index of suspicious to infection with atypical mycobacterium, especially Mycobacterium simiae in patients presenting with signs and symptoms of mycobacterium tuberculosis infection. Therefore, appropriate diagnostic tests and evaluation procedures should be considered.
